FROM PUBLIC EVENTS · 2026-11-15

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Pipeline reshaping After its partner reported Phase 3 results for the first molecule, development is shifting to the successor.

  • The partner reported Phase 3 results for batoclimab in thyroid eye disease. Source

Roles often seen at this stageBD & licensing · Clinical & PV · Research & development

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-15

HanAll Biopharma

A biopharmaceutical company that has licensed autoimmune antibody candidates to overseas partners and sells medicines in Korea.

Batoclimab

Phase 3

FcRn antibody whose partner reported thyroid eye disease Phase 3 results and is focusing on its successor molecule.

IMVT-1402

Stage unconfirmed

Next-generation FcRn antibody whose development the partner is accelerating.

Completion reported

The partner reported results of two Phase 3 trials of batoclimab in thyroid eye disease.

Official role guide

HanAll Biopharma careers

Current availability unconfirmed

Observed 2026-11-15

Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.

Information from a role guide does not establish a current vacancy.

Sources & coverage 1

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 한올바이오, 차세대 물질 주목받는 이유는 ↗네이트 뉴스 · Published 2026-04-10 · Sources checked 2026-11-15 · Original unavailable